Organization
Natera Inc.
4 abstracts
Abstract
Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404.Org: Natera Inc., UCLA, Jonsson Comprehensive Cancer Center,
Abstract
Circulating tumor DNA and association with CAR-T cell therapy response in gastric and pancreatic cancer patients.Org: Natera Inc., CARsgen Therapeutics, Inc, Houston, TX,
Abstract
Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis.Org: Natera, Inc., Stanford University Medical Center, Stanford, CA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Rush University Medical Center, Stanford Cancer Center,
Abstract
ctDNA detection before and during systemic therapy for inflammatory breast cancer.Org: Natera, Inc., Natera Inc., Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Rutgers Cancer Institue of New Jersey, Baylor College of Medicine,